DISCOVER THE POWER OF EXPERIENCE

Over a decade of real-world experience treating relapsing MS1

OVER
200,000
PATIENTS TREATED

globally for relapsing MS with the established therapy of TYSABRI, and counting2,a

MORE THAN
15 YEARS
OF EXPERIENCE

in clinical trials and real-world use. Biogen is committed to patient safety through the TOUCH® Prescribing Program

APPROXIMATELY
1 IN 3
NEW PATIENTS

in the US who start
TYSABRI have received
no previous DMT3,b

DMT=disease-modifying therapy.
a213,000 patients as of July 2020.2
b36.9% of patients as of April 2020.3

REAL EXPERIENCES
WITH TYSABRI

Leading physicians describe the value of real-world experience (10+ years) when considering an appropriate DMT.